G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 1:30 PM EDT. CEO Jack Bailey and other executives will engage in a fireside chat during the event, which will be held virtually. Interested parties can access the webcast through the Events & Presentations page on G1 Therapeutics' website. The company focuses on developing next-generation therapies for cancer treatment, including its first product, COSELA® (trilaciclib). G1 Therapeutics is based in Research Triangle Park, North Carolina, and is committed to improving the lives of cancer patients through innovative therapies.

RESEARCH TRIANGLE PARK, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey and other members of the Executive Team will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference. The fireside chat will take place on Tuesday April 18th at 1:30 PM EDT.

This meeting is being held virtually; the webcast of the event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a development plan evaluating trilaciclib in a variety of solid tumors, including breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc

Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com

FAQ

When will G1 Therapeutics participate in the Needham Virtual Healthcare Conference?

G1 Therapeutics will participate in the Needham Virtual Healthcare Conference on April 18, 2023, at 1:30 PM EDT.

Who from G1 Therapeutics will be speaking at the conference?

CEO Jack Bailey and other members of the Executive Team will be speaking at the conference.

How can I access the G1 Therapeutics conference webcast?

The webcast of G1 Therapeutics' session at the conference can be accessed on their Events & Presentations page on their website.

What is the significance of COSELA® for G1 Therapeutics?

COSELA® (trilaciclib) is G1 Therapeutics' first commercial product, aimed at improving cancer treatment outcomes.

What types of cancers is G1 Therapeutics targeting with its therapies?

G1 Therapeutics is developing therapies for various solid tumors, including breast, lung, and bladder cancers.